Dataset from See Detailed Description

This study was designed to test the efficacy, safety, tolerability and durability of the antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC) Fixed dose combination (FDC) each administered once daily (QD) for 36 weeks followed by randomization to either a simplification regimen of ATV or continuation of ATV +/r for an additional 48 weeks, each in combination with ABC/3TC in antiretroviral (ART)-naive, HIV-1 infected, HLA-B*5701 negative subjects. All subjects who complete the 84-week study will be eligible to enter the treatment extension phase and continue for an additional 60 weeks. The purpose of this extension is to obtain longer term treatment data in subjects who have completed the 84-week study.本研究旨在评估两种后续治疗方案的抗病毒应答效力、安全性、耐受性及持久性：受试者先每日一次（QD）服用阿扎那韦（atazanavir, ATV）+利托那韦（ritonavir, /r）+阿巴卡韦/拉米夫定（abacavir/lamivudine, ABC/3TC）固定剂量复方制剂（fixed dose combination, FDC），持续给药36周；随后将抗反转录病毒治疗（antiretroviral, ART）初治、HIV-1感染且HLA-B*5701阴性的受试者随机分为两组，一组接受阿扎那韦简化治疗方案，另一组继续联合ABC/3TC使用ATV+/r治疗，两组均额外接受48周治疗。 所有完成84周研究的受试者均有资格进入治疗扩展阶段，继续接受最长60周的治疗。本扩展阶段的目的是获取完成84周研究的受试者的长期治疗数据。